Watchlist Price Alert

Rezolute Inc. (RZLT)

NASDAQ: RZLT · Real-Time Price · USD

3.67

-0.05 (-1.34%)

At close: May 09, 2025, 3:59 PM

3.93

6.94%

After-hours: May 09, 2025, 05:45 PM EDT

-1.34% (1D)

Bid	3.53
Market Cap	298.86M
Revenue (ttm)	58K
Net Income (ttm)	-71.13M
EPS (ttm)	-1.23
PE Ratio (ttm)	-2.99
Forward PE	-2.95
Analyst	Buy

Ask	3.93
Volume	468,381
Avg. Volume (20D)	963,770
Open	3.72
Previous Close	3.72
Day's Range	3.63 - 3.89
52-Week Range	2.21 - 6.19
Beta	1.02

About RZLT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RZLT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RZLT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+27.65%

Rezolute shares are trading higher after the compa... Unlock content with Pro Subscription

8 months ago

+22.07%

Rezolute shares are trading higher after the company announced the FDA has removed the partial clinical holds on RZ358.

News

1 week ago · seekingalpha.com

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

Topline results from phase 3 sunRIZE study, using ersodetug for the treatment of patients with congenital hyperinsulinism, expected in December 2025. Proof-of-concept was established in a phase 2 stud...

2 weeks ago · benzinga.com

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Rezolute, Inc. RZLT on Wednesday announced the Independent Data Monitoring Committee's (DMC) recommendation to continue the Phase 3 sunRIZE study as planned in patients with congenital hyperinsulinism...

4 weeks ago · zacks.com

Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock?

Rezolute (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulin...